Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
Yahoo Finance · Nov 4, 2026 · Novo Nordisk A S (NVO)
4 November - Financial report for the period 1 January 2026 to 30 September 2026Financial performance Q3 2026 adjusted and reported sales increased by 4% at CER, driven by continued GLP-1 volume growth across the US and International operations, primarily in obesity.Q3 2026 adjusted operating profit increased by 27% at CER, driven by GLP-1 sales growth and a favourable comparison base following DKK 9 billion of company-wide transformation costs recognised in Q3 2025.Q3 2026 reported operating pr
Not investment advice. Headline and summary only, not a full reprint.